Literature DB >> 22399503

A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody.

Seema Kumar1, Seethalakshmi Iyer, Hilary Bauer, Michael Coenen, Rebecca S Bahn.   

Abstract

CONTEXT: Graves' ophthalmopathy (GO) is characterized by expanded volume of the orbital fat and extraocular muscle tissues and elevated levels of TSH receptor autoantibodies (TRAb). The expansion of orbital tissues involves accumulation of hyaluronic acid (HA) within the orbit.
OBJECTIVE: The objective of the study was to determine whether a monoclonal stimulatory TRAb (M22) impacts HA synthesis in GO orbital cells and, if so, whether this might be blocked by an IGF-I receptor (IGF-IR)-blocking antibody (1H7) or inhibitors of various downstream signaling cascades.
DESIGN: GO orbital fibroblast cultures (n = 6) were treated with M22, bovine TSH (bTSH), or IGF-I in serum-free medium. Some cultures also received 1H7, LY294002, rapamycin, or protein kinase A inhibitor. MAIN OUTCOME MEASURES: HA production and phosphorylated Akt levels in media or immunoblotting for phosphorylated Akt were measured.
RESULTS: M22 or bTSH stimulated HA synthesis (2.1-fold with 100 ng/ml M22 and 1.9-fold with 10 U/liter bTSH; P < 0.05 each). M22-induced HA synthesis was inhibited by LY294002 or rapamycin but not by protein kinase inhibitor. HA synthesis stimulated by M22 or IGF-I was inhibited by 1H7 (mean 36.6 ± 5.6% and mean 45.8 ± 7.6%, respectively; P < 0.05 each). Similarly, M22- or IGF-I-stimulated Akt phosphorylation was inhibited by 1H7 (mean 54 ± 9.6 and 36.1 ± 8.8%, respectively; P = 0.01 each).
CONCLUSIONS: The stimulatory TRAb M22 increases HA production in undifferentiated GO orbital fibroblasts via phosphoinositide 3-kinase/phosphorylated AKT/mammalian target of rapamycin activation. Blockade of IGF-IR inhibits both HA synthesis and Akt phosphorylation induced by M22 or IGF-I in these cells, suggesting that TSH receptor and IGF-IR signaling may be closely linked in the GO orbit.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22399503      PMCID: PMC3339886          DOI: 10.1210/jc.2011-2890

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

1.  Effect of growth factors on hyaluronan and proteoglycan synthesis by retroocular tissue fibroblasts of Graves' ophthalmopathy in culture.

Authors:  Y Imai; R Odajima; Y Inoue; Y Shishiba
Journal:  Acta Endocrinol (Copenh)       Date:  1992-06

2.  Stimulation of glycosaminoglycan production in cultured human retroocular fibroblasts.

Authors:  J M Korducki; S J Loftus; R S Bahn
Journal:  Invest Ophthalmol Vis Sci       Date:  1992-05       Impact factor: 4.799

3.  Gene expression profiling of orbital adipose tissue from patients with Graves' ophthalmopathy: a potential role for secreted frizzled-related protein-1 in orbital adipogenesis.

Authors:  Seema Kumar; Alexey Leontovich; Michael J Coenen; Rebecca S Bahn
Journal:  J Clin Endocrinol Metab       Date:  2005-05-10       Impact factor: 5.958

4.  Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor.

Authors:  R W Valyasevi; D Z Erickson; D A Harteneck; C M Dutton; A E Heufelder; S C Jyonouchi; R S Bahn
Journal:  J Clin Endocrinol Metab       Date:  1999-07       Impact factor: 5.958

5.  Construction and characterization of single-chain antibodies against human insulin-like growth factor-I receptor from hybridomas producing 1H7 or 3B7 monoclonal antibody.

Authors:  Yu Kusada; Toru Morizono; Ayano Matsumoto-Takasaki; Keiko Sakai; Shuma Sato; Hideki Asanuma; Atsushi Takayanagi; Yoko Fujita-Yamaguchi
Journal:  J Biochem       Date:  2007-10-23       Impact factor: 3.387

6.  Thyrotropin receptor activation increases hyaluronan production in preadipocyte fibroblasts: contributory role in hyaluronan accumulation in thyroid dysfunction.

Authors:  Lei Zhang; Timothy Bowen; Fiona Grennan-Jones; Carol Paddon; Peter Giles; Jason Webber; Robert Steadman; Marian Ludgate
Journal:  J Biol Chem       Date:  2009-07-24       Impact factor: 5.157

7.  Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease.

Authors:  Shanli Tsui; Vibha Naik; Neil Hoa; Catherine J Hwang; Nikoo F Afifiyan; Amiya Sinha Hikim; Andrew G Gianoukakis; Raymond S Douglas; Terry J Smith
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

8.  The superagonistic activity of bovine thyroid-stimulating hormone (TSH) and the human TR1401 TSH analog is determined by specific amino acids in the hinge region of the human TSH receptor.

Authors:  Sandra Mueller; Gunnar Kleinau; Mariusz W Szkudlinski; Holger Jaeschke; Gerd Krause; Ralf Paschke
Journal:  J Biol Chem       Date:  2009-04-22       Impact factor: 5.157

9.  Characterization of thyrotropin receptor antibody-induced signaling cascades.

Authors:  Syed A Morshed; Rauf Latif; Terry F Davies
Journal:  Endocrinology       Date:  2008-08-21       Impact factor: 4.736

10.  Thyroid stimulating immunoglobulins, like thyrotropin activate both the cyclic AMP and the PIP2 cascades in CHO cells expressing the TSH receptor.

Authors:  J Van Sande; C Lejeune; M Ludgate; D S Munro; G Vassart; J E Dumont; J Mockel
Journal:  Mol Cell Endocrinol       Date:  1992-10       Impact factor: 4.102

View more
  27 in total

1.  Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye Disease.

Authors:  Susanne Neumann; Christine C Krieger; Marvin C Gershengorn
Journal:  Eur Thyroid J       Date:  2020-11-02

Review 2.  TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy.

Authors:  Terry J Smith
Journal:  Nat Rev Endocrinol       Date:  2015-01-06       Impact factor: 43.330

3.  Emerging pharmacotherapy for treatment of Graves' disease.

Authors:  Rebecca S Bahn
Journal:  Expert Rev Clin Pharmacol       Date:  2012-11       Impact factor: 5.045

4.  Is IGF-I receptor a target for autoantibody generation in Graves' disease?

Authors:  Terry J Smith
Journal:  J Clin Endocrinol Metab       Date:  2013-02       Impact factor: 5.958

5.  PI3K/AKT pathway mediates induction of IL-1RA by TSH in fibrocytes: modulation by PTEN.

Authors:  Bin Li; Terry J Smith
Journal:  J Clin Endocrinol Metab       Date:  2014-05-19       Impact factor: 5.958

6.  Inhibiting thyrotropin/insulin-like growth factor 1 receptor crosstalk to treat Graves' ophthalmopathy: studies in orbital fibroblasts in vitro.

Authors:  Robert F Place; Christine C Krieger; Susanne Neumann; Marvin C Gershengorn
Journal:  Br J Pharmacol       Date:  2017-01-27       Impact factor: 8.739

7.  Arrestin-β-1 Physically Scaffolds TSH and IGF1 Receptors to Enable Crosstalk.

Authors:  Christine C Krieger; Alisa Boutin; Daesong Jang; Sarah J Morgan; J Paul Banga; George J Kahaly; Joanna Klubo-Gwiezdzinska; Susanne Neumann; Marvin C Gershengorn
Journal:  Endocrinology       Date:  2019-06-01       Impact factor: 4.736

Review 8.  TSH/IGF1 receptor crosstalk: Mechanism and clinical implications.

Authors:  Christine C Krieger; Susanne Neumann; Marvin C Gershengorn
Journal:  Pharmacol Ther       Date:  2020-02-13       Impact factor: 12.310

9.  Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins.

Authors:  Christine C Krieger; Susanne Neumann; Robert F Place; Bernice Marcus-Samuels; Marvin C Gershengorn
Journal:  J Clin Endocrinol Metab       Date:  2014-12-08       Impact factor: 5.958

10.  A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy.

Authors:  Adina F Turcu; Seema Kumar; Susanne Neumann; Michael Coenen; Seethalakshmi Iyer; Pamela Chiriboga; Marvin C Gershengorn; Rebecca S Bahn
Journal:  J Clin Endocrinol Metab       Date:  2013-03-12       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.